Anxiety Associated With the Use of the Electrocardiogram Function in Smart Watches

Last updated: April 3, 2024
Sponsor: ITMO University
Overall Status: Completed

Phase

N/A

Condition

Depression

Anxiety Disorders

Mood Disorders

Treatment

Electrocardiogram (ECG) feature in smart watches

Clinical Study ID

NCT06131463
be-healthy-smart-watches
  • Ages 22-100
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

The integration of electrocardiography (ECG) functionality into smartwatches is primarily intended to screen for atrial fibrillation, a frequent cause of ischemic stroke, among people aged 50 years and older. However, it should be noted that recommendations for atrial fibrillation screening are controversial, and several organizations and communities do not recommend screening outside of at-risk groups.

Some smart device manufacturers do not recommend using the ECG function for anyone under the age of 22. However, young people are frequent users of wearable devices. One of the most common cardiologic diseases at the age of 18-30 is benign heart rhythm disorder, which often does not require diagnosis or treatment and can be considered normal.

That said, notification of the detection of atrial fibrillation can affect psycho-emotional well-being, particularly anxiety.

This study will assess the level of psycho-emotional health (anxiety level) of the study participants. Participant observation will provide an opportunity to identify associations between the use of the ECG recording function on wearable devices and levels of anxiety and depression. It is hypothesized that the use of smartwatches with the ECG function activated will not lead to a change in anxiety levels on the GAD-7 scale among the study participants. This assumes that after 30 days of use, the mean value of the GAD-7 scale in the intervention group and the control group will be the same.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Status of a student or employee of ITMO University;
  • Availability of a smart watch with ECG function (Apple Watch Series 4 and newer,Galaxy Watch Active2, Samsung Galaxy Watch Series 3 and newer or similar with ECGfunction);
  • Availability of a Galaxy smartphone running Android 7.0 or newer or availability of aniPhone 8 and newer smartphone with the latest version of iOS.
  • Signed Informed consent and Consent for Data Processing of Personal Data;
  • Absence of previously diagnosed clinically significant cardiovascular pathology.

Exclusion

Exclusion Criteria:

  • Participants under the age of 22 cannot be included in the study;
  • Participants in the acute phase of any disease or in the exacerbation of chronicdiseases are excluded from the study.

Study Design

Total Participants: 71
Treatment Group(s): 1
Primary Treatment: Electrocardiogram (ECG) feature in smart watches
Phase:
Study Start date:
November 13, 2023
Estimated Completion Date:
March 04, 2024

Connect with a study center

  • ITMO University

    Saint Petersburg, 197101
    Russian Federation

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.